23andMe hit with class-action lawsuit; Glass Dx tools with trained honeybees help spot cancer;

> 23andMe now faces a class-action lawsuit claiming the company misled customers by selling genetic tests with no real scientific value. Story

> Roche ($RHHBY) is launching a new lab instrument for high-volume processing of molecular diagnostic samples. Item

> A University of Toronto spinout nailed down $18.8 million in a Series B financing that will help advance its rapid-use molecular diagnostic technology in the U.S. Story

> A new blood test can detect a person's risk of infection from a drop of blood within minutes, according to a study published in the journal Technology. Story

> A Portuguese designer has developed a series of glass diagnostic tools that use trained honeybees to determine if a patient has cancer. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.